Fludarabine
B-Cell Adult Acute Lymphocytic Leukemia
Explore 23 assets in B-Cell Adult Acute Lymphocytic Leukemia →Floatz Rating
B56/100
Confidence
Indicative
Sponsor
The First Affiliated Hospital of Soochow University
Modality
Small molecule
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06696833CT.gov Allogeneic CD19-targeted CAR-γδT Cell Infusion Therapy in Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia | — | Recruiting | — | — | — |
NCT04626726CT.gov Adult B-ALL Treated by CART Cell Bridging Allogeneic Hematopoietic Stem Cell Transplantation | — | Unknown | — | — | — |
NCT04214886CT.gov CD19 Chimeric Antigen Receptor (CAR) T Cells for Adults With Recurrent or Refractory B Cell Malignancies | — | Active Not Recruiting | — | — | — |
NCT03110640CT.gov Anti-CD19 CAR T Infusion Combined With Allogeneic Stem Cell Transplantation for B-cell Leukemia/Lymphoma | — | Unknown | — | — | — |
NCT02685670CT.gov Competitive Transfer of αCD19-TCRz-CD28 and αCD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/Lymphoma | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · B-Cell Adult Acute Lymphocytic Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Fludarabine (this asset) | The First Affiliated Hospital of Soochow University | P1/2 | B · 56 |
| Vincristine Sulfate | SWOG Cancer Research Network | P3 | BBB |
| Pegaspargase | National Cancer Institute (NCI) | P3 | BBB |
| Cytarabine | Massachusetts General Hospital | P3 | BBB |
| Cyclophosphamide | The First Affiliated Hospital of Soochow University | P3 | BBB |
| Dexasone | Mayo Clinic | P3 | BBB |
| Mercaptopurine Anhydrous | Massachusetts General Hospital | P3 | BBB |
| Prednisone | SWOG Cancer Research Network | P3 | BBB |
| Methotrexate | Massachusetts General Hospital | P3 | BBB |
+42 more in the B-Cell Adult Acute Lymphocytic Leukemia cohort
Other indications for Fludarabine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Adult T-Cell Leukemia/Lymphoma | — | P2 | BBB · 76 |
| Acute Myeloid Leukemia With Abnormal Bone Marrow Eosinophils Inv(16)(P13q22) Or T(16;16)(P13;Q22) | — | P2 | BBB · 76 |
| Fanconi Anemia | — | P2/3 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Fludarabine in B-Cell Adult Acute Lymphocytic Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/fludarabine-b-cell-adult-acute-lymphocytic-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →